REGISTER
Whether lorlatinib should be prioritized as first-line therapy
Prof. Solomon discussed whether lorlatinib should be prioritized as first-line therapy for newly diagnosed advanced ALK-positive NSCLC based on the long-term CROWN results.

Prof. Benjamin Solomon, Peter MacCallum Cancer Centre, Australia


Prof. Solomon discussed whether lorlatinib should be prioritized as first-line therapy for newly diagnosed advanced ALK-positive NSCLC based on the long-term CROWN results, and whether selected patients on earlier-generation ALK TKIs may benefit from an earlier switch to optimize long-term outcomes. He also shared his perspectives on treatment selection for patients without baseline brain metastases, the concept of clinical cure with long-term TKI therapy, and potential biomarkers for predicting long-term prognosis.

0
0
Loading